Royalty Pharma plc
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Royalty Pharma plc now
Current reporting with the operating signal separated from the noise.
Royalty Pharma plc Announces Appointment of Greg Raskin as Senior Vice President, Head of Academic Initiatives, Effective August 2026
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.The Manufacturers Life Insurance Company Buys 219,772 Shares of Royalty Pharma PLC $RPRX
Investors are testing whether Royalty Pharma plc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Quantinno Capital Management LP Buys 41,417 Shares of Royalty Pharma PLC $RPRX
Investors are testing whether Royalty Pharma plc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Dimensional Fund Advisors LP Has $51.67 Million Holdings in Royalty Pharma PLC $RPRX
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Carmignac Gestion Purchases Shares of 631,200 Royalty Pharma PLC $RPRX
Investors are testing whether Royalty Pharma plc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Transamerica Capital Growth's Royalty Pharma PLC(RPRX) Holding History
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.RPRX|Royalty Pharma PLC|Price:57.310|Chg%:-1.120
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis
Investors are testing whether Royalty Pharma plc’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Royalty Pharma PLC (RPRX) Valuation: PE, PB & Fair Value Analysis
The development tests whether Royalty Pharma plc can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Royalty Pharma PLC (RPRX) Institutional Confidence
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Royalty Pharma plc: Royalty Pharma declares third quarter 2026 dividend
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest RPRX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Royalty Pharma plc, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →